MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. announced a class-action lawsuit against Mereo BioPharma Group plc (NASDAQ:MREO) on behalf of investors who purchased shares between June 5, 2023, and December 26, 2025. The lawsuit alleges that Mereo made misleading statements regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which ultimately failed to meet their primary endpoints, causing a significant stock price decline. Investors have until April 6, 2026, to apply to be lead plaintiff.
MAR 14·www.marketscreener.com→
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)
Holzer & Holzer, LLC is reminding investors of the April 6, 2026, lead plaintiff deadlines for several shareholder class action lawsuits. These lawsuits are filed against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE). The firm encourages investors who suffered significant losses during the specified periods to contact them to discuss their legal rights.
FEB 18·GlobeNewswire▼
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds
Bragar Eagel & Squire, P.C. has reminded investors that class action lawsuits have been filed against Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc. The lawsuits allege that both companies made materially false and misleading statements regarding the Phase III Orbit and Cosmic Studies for setrusumab in patients with Osteogenesis Imperfecta, leading to significant stock price declines when the studies failed to meet primary endpoints. Investors are encouraged to contact the firm by April 6, 2026, to serve as lead plaintiff.
